Pharma’s $500B patent problem will come in waves — not as a cliff
Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.